Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BCRX Biocryst Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: BCRX
Price (delayed)
$8.71
Market cap
$1.82B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$2.55B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of
Highlights
BCRX's EPS has soared by 76% YoY and by 40% from the previous quarter
The net income has surged by 74% year-on-year and by 40% since the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 17% YoY but it has increased by 12% QoQ
Key stats
What are the main financial stats of BCRX
Market
Valuations
Earnings
Shares outstanding
209.25M
Market cap
$1.82B
Enterprise value
$2.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.61
EV/EBIT
54.97
EV/EBITDA
53.5
EV/Sales
5.06
Revenue
$503.49M
Gross profit
$487.82M
Operating income
$33.17M
Net income
-$53.47M
EBIT
$46.32M
EBITDA
$47.59M
Free cash flow
-$26.89M
Per share
Balance sheet
Liquidity
EPS
-$0.26
EPS diluted
-$0.26
Free cash flow per share
-$0.13
Book value per share
-$2.16
Revenue per share
$2.41
TBVPS
$2.3
Total assets
$480.05M
Total liabilities
$931.97M
Debt
$829.29M
Equity
-$451.93M
Working capital
$270.12M
Debt to equity
-1.84
Current ratio
2.93
Quick ratio
2.78
Net debt/EBITDA
15.21
Margins
Efficiency
Dividend
EBITDA margin
9.5%
Gross margin
96.9%
Net margin
-10.6%
Operating margin
6.6%
Return on assets
-11.1%
Return on equity
N/A
Return on invested capital
4.3%
Return on capital employed
13.6%
Return on sales
9.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCRX stock price
How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-2.79%
1 week
-0.91%
1 month
-16.01%
1 year
21.31%
YTD
15.82%
QTD
-2.79%
Financial performance
How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$503.49M
Gross profit
$487.82M
Operating income
$33.17M
Net income
-$53.47M
Gross margin
96.9%
Net margin
-10.6%
BCRX's operating income has soared by 137% YoY
The operating margin has soared by 126% YoY
BCRX's net margin has soared by 82% YoY and by 46% QoQ
The net income has surged by 74% year-on-year and by 40% since the previous quarter
Price vs fundamentals
How does BCRX's price correlate with its fundamentals
Growth
What is Biocryst Pharmaceuticals's growth rate over time
Valuation
What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.61
EV/EBIT
54.97
EV/EBITDA
53.5
EV/Sales
5.06
BCRX's EPS has soared by 76% YoY and by 40% from the previous quarter
BCRX's equity is up by 5% year-on-year and by 5% since the previous quarter
The P/S is 76% lower than the 5-year quarterly average of 15.2 but 9% higher than the last 4 quarters average of 3.4
BCRX's revenue is up by 42% YoY and by 12% QoQ
Efficiency
How efficient is Biocryst Pharmaceuticals business performance
The ROIC has soared by 146% YoY
BCRX's ROS has soared by 132% YoY
The company's return on assets has surged by 73% YoY and by 40% QoQ
Dividends
What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCRX.
Financial health
How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 48% lower than its total liabilities
Biocryst Pharmaceuticals's current ratio has decreased by 21% YoY but it has increased by 11% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 17% YoY but it has increased by 12% QoQ
BCRX's equity is up by 5% year-on-year and by 5% since the previous quarter
BCRX's debt to equity is down by 4% since the previous quarter and by 2.8% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.